
Quarterly report 2025-Q4
added 02-13-2026
Beyond Air Revenue 2011-2026 | XAIR
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Beyond Air
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.7 M | 1.16 M | - | - | 873 K | 1.39 M | 7.72 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 7.72 M | 873 K | 2.97 M |
Quarterly Revenue Beyond Air
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.19 M | 1.82 M | 1.76 M | - | 1.07 M | 798 K | 683 K | - | 391 K | 239 K | 59 K | - | - | - | - | - | - | - | - | - | 149 K | 149 K | 350 K | 229 K | 314 K | 314 K | 646 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.19 M | 59 K | 698 K |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
AxoGen
AXGN
|
225 M | $ 32.5 | -8.14 % | $ 1.44 B | ||
|
Acutus Medical
AFIB
|
7.16 M | - | -26.83 % | $ 2.62 M | ||
|
Allied Healthcare Products
AHPI
|
6.02 M | - | 3.58 % | $ 2.21 M | ||
|
Apollo Endosurgery
APEN
|
76.9 M | - | - | $ 475 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
172 M | - | - | $ 1.77 B | ||
|
Avinger
AVGR
|
7.65 M | - | -20.74 % | $ 369 K | ||
|
Aziyo Biologics
AZYO
|
24.7 M | - | 1.37 % | $ 20.5 M | ||
|
Alphatec Holdings
ATEC
|
764 M | $ 13.77 | 4.86 % | $ 1.97 B | ||
|
Bio-Rad Laboratories
BIO
|
2.57 B | $ 269.87 | 0.53 % | $ 7.61 B | ||
|
BIOLASE
BIOL
|
49.2 M | - | -13.19 % | $ 166 K | ||
|
Obalon Therapeutics, Inc.
OBLN
|
1.59 M | - | -5.86 % | $ 30.6 M | ||
|
Axonics Modulation Technologies
AXNX
|
274 M | - | - | $ 3.31 B | ||
|
Apyx Medical Corporation
APYX
|
52.3 M | $ 3.53 | -1.12 % | $ 122 M | ||
|
Conformis
CFMS
|
62 M | - | - | $ 16.4 M | ||
|
ClearPoint Neuro
CLPT
|
31.4 M | $ 14.58 | -1.22 % | $ 394 M | ||
|
Cognyte Software Ltd.
CGNT
|
443 M | $ 6.36 | 0.32 % | $ 457 M | ||
|
Cardiovascular Systems
CSII
|
236 M | - | 0.15 % | $ 844 M | ||
|
Bruker Corporation
BRKR
|
3.37 B | $ 39.87 | 0.77 % | $ 5.94 K | ||
|
BioSig Technologies
BSGM
|
40 K | - | 37.08 % | $ 85.7 M | ||
|
Boston Scientific Corporation
BSX
|
20.1 B | $ 75.27 | 1.21 % | $ 111 B | ||
|
EDAP TMS S.A.
EDAP
|
44.1 M | $ 4.52 | - | $ 169 M | ||
|
CryoLife, Inc.
CRY
|
253 M | - | -4.14 % | $ 702 M | ||
|
Dynatronics Corporation
DYNT
|
27.4 M | - | 14.99 % | $ 929 K | ||
|
Electromed
ELMD
|
64 M | $ 23.17 | -5.16 % | $ 196 M | ||
|
CONMED Corporation
CNMD
|
1.37 B | $ 46.0 | 1.39 % | $ 1.43 B | ||
|
Second Sight Medical Products
EYES
|
1 K | - | -0.97 % | $ 54.4 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
41 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
62.5 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
2.55 M | - | - | $ 111 M | ||
|
GBS
GBS
|
3.05 M | - | -0.57 % | $ 7.12 M | ||
|
Cutera
CUTR
|
49.5 M | - | -10.19 % | $ 1.99 M | ||
|
Delcath Systems
DCTH
|
37.2 M | $ 9.94 | 2.0 % | $ 283 M | ||
|
Intersect ENT, Inc.
XENT
|
80.6 M | - | - | $ 955 M | ||
|
Eargo
EAR
|
37.2 M | - | - | $ 10.2 M | ||
|
InMode Ltd.
INMD
|
358 M | $ 14.0 | -1.41 % | $ 905 M | ||
|
Establishment Labs Holdings
ESTA
|
166 M | $ 78.78 | 5.1 % | $ 2.22 B | ||
|
IRadimed Corporation
IRMD
|
73.2 M | $ 99.04 | -2.22 % | $ 1.25 B | ||
|
Invacare Corporation
IVC
|
181 M | - | - | $ 24.7 M | ||
|
FONAR Corporation
FONR
|
97.6 M | $ 18.55 | -0.22 % | $ 122 M | ||
|
Globus Medical
GMED
|
2.94 B | $ 92.25 | -1.25 % | $ 12.5 B | ||
|
LivaNova PLC
LIVN
|
1.25 B | $ 69.26 | 1.32 % | $ 3.76 B | ||
|
Pulmonx Corporation
LUNG
|
83.8 M | $ 1.51 | 2.03 % | $ 59.1 M | ||
|
Helius Medical Technologies
HSDT
|
644 K | $ 1.88 | - | $ 1.14 M | ||
|
Medtronic PLC
MDT
|
33.5 B | $ 97.06 | -1.57 % | $ 125 B | ||
|
Integra LifeSciences Holdings Corporation
IART
|
1.61 B | $ 11.57 | -1.66 % | $ 891 M | ||
|
MiMedx Group
MDXG
|
349 M | $ 5.35 | 0.28 % | $ 786 M |